Axiom Biosciences Partners with GeneFab to Boost Manufacturing and Clinical Development Capabilities

SAN DIEGO, Sept. 15, 2026 /CourierPR/ -- Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, has announced a strategic partnership with GeneFab, a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. This collaboration aims to bolster Axiom’s manufacturing and clinical development capabilities, ensuring the company is well-prepared for upcoming activities across its lead therapeutic programs.

According to Dr. Remo Moomiaie-Qajar, Founder and CEO of Axiom Biosciences, establishing the right manufacturing and clinical infrastructure is crucial for advancing the company’s therapeutic programs. GeneFab will provide development and manufacturing support, focusing on establishing scalable, reproducible production processes that meet the quality standards and regulatory requirements of clinical-stage development. This partnership will help Axiom build the necessary manufacturing infrastructure to support the continued progression of its therapeutic candidates.

Moomiaie-Qajar.

Axiom Biosciences, formerly Cytonus Therapeutics, is headquartered in San Diego, California. The company is developing next-generation regenerative therapies and targeted biologics through advanced cellular engineering and translational science. Its pipeline includes programs aimed at addressing some of the most challenging diseases across neurology, inflammation, and regenerative medicine. Axiom Biosciences is advancing programs from rare pediatric conditions toward larger indications, including adult ischemic stroke.

GeneFab, founded in 2023, is based in the Bay Area, California. The company partners with innovators to design, develop, and manufacture transformative therapies through an integrated technology platform that spans synthetic biology, in vivo vectors, and autologous and allogeneic ex vivo cell therapy production. GeneFab’s focus on cGMP-compliant cell and gene therapies positions it as a valuable partner for Axiom Biosciences.

The partnership between Axiom Biosciences and GeneFab is expected to streamline the development and manufacturing processes, ultimately supporting Axiom’s mission to improve and advance therapies for patients. By leveraging GeneFab’s expertise, Axiom Biosciences aims to accelerate the advancement of its therapeutic programs and bring innovative treatments to market more efficiently.